SCHEMBL765494

SCHEMBL765494

CCc1ccc(OCF)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
NQO1 P15559 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SOD1 P00441 1/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
KMT2A Q03164 1/20 0.43
CYP2A6 P11509 1/20 0.43
CYP2C19 P33261 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
APP P05067 2/20 0.41
CISD1 Q9NZ45 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19829092 0.94 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL13569352 0.82 APP (0.61) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL13925522 0.82 APP (0.61) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL3719994 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1LMNANQO1L3MBTL1
SCHEMBL26128025 0.82 NQO1 (0.47) ALDH1A1NQO1TDP1APP
SCHEMBL13925526 0.80 LMNA (0.58) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL31423 0.80 NQO1 (0.74) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL14588243 0.80 NQO1 (0.74) SMN1; SMN2ALDH1A1LMNAMAPTNQO1
SCHEMBL5929490 0.80 MAPT (0.62) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL17445912 0.78 ALDH1A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781661-B1 VASOPRESSIN V1A ANTAGONISTS VANTIA LTD (GB) 2017-06-07 EP disclosed
US-20140371223-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS ADDEX PHARMA S.A. (CH) 2014-12-18 US disclosed
US-20130302282-A1 Inhibitors of Hepatitis C Virus PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-14 US disclosed
US-20120101082-A1 VASOPRESSIN V1A ANTAGONISTS BATT ANDRZEJ ROMAN (GB) 2012-04-26 US disclosed
EP-1954668-B9 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-21 EP disclosed
EP-1915345-B1 FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-22 EP disclosed
EP-1045836-B1 PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS BOEHRINGER INGELHEIM PHARMA (US) 2008-03-05 EP disclosed
EP-1345943-B1 INHIBITORS OF PAPILLOMA VIRUS BOEHRINGER INGELHEIM CA LTD (CA) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371223-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS CHRNA5, GABRA5, GABRB3 SMN1; SMN2 301/4885ALDH1A1 3515/4885LMNA 3784/4885
US-20130302282-A1 Inhibitors of Hepatitis C Virus HAVCR2, LIPC, HCCS SMN1; SMN2 4681/4885ALDH1A1 1654/4885LMNA 2548/4885
US-20120101082-A1 VASOPRESSIN V1A ANTAGONISTS AVPR1A, AVPR2, AVPR1B SMN1; SMN2 4623/4885ALDH1A1 902/4885LMNA 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.